Evidence map›Paper›PMID 37161607›Full record

ArticleCardiovascular research2023

Nedd4-2 up-regulation is associated with ACE2 ubiquitination in hypertension.

Mazher Mohammed, Blessing Ogunlade, Mona Elgazzaz, Clara Berdasco, Navya Lakkappa, Ioana Ghita, Jessie J Guidry, Srinivas Sriramula, Jiaxi Xu, Luke Restivo and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Cardiovascular research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. NEDD4L induces mitochondrial dysfunction and neurodegeneration by promoting LIPT2 degradation in Huntington's disease.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Review
  7. Nanomedicine (London, England) · 2025
    Article
  8. Analysis of modifying factors for ACE2 to work effectively.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Alternative Renin-Angiotensin System.Hypertension (Dallas, Tex. : 1979) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 3 countries.

Mazher MohammedSoutheast Louisiana Veterans Health Care System, 2400 Canal Street, New Orleans, LA 70119, USA.ORCID 0000-0002-6728-1930
Blessing OgunladeDepartment of Pharmacology, School of Medicine, Howard University, 520 W St, NW, Washington, DC 20059, USA.ORCID 0000-0002-4256-4547
Mona ElgazzazSoutheast Louisiana Veterans Health Care System, 2400 Canal Street, New Orleans, LA 70119, USA.ORCID 0000-0002-8437-2789
Clara BerdascoSoutheast Louisiana Veterans Health Care System, 2400 Canal Street, New Orleans, LA 70119, USA.ORCID 0000-0001-6704-9763
Navya LakkappaSoutheast Louisiana Veterans Health Care System, 2400 Canal Street, New Orleans, LA 70119, USA.ORCID 0000-0003-2079-5675
Ioana GhitaDepartment of Oncology and Diagnostic Sciences, School of Dentistry, University of Maryland, Baltimore, MD 21201, USA.
Jessie J GuidryDepartment of Pharmacology & Experimental Therapeutics, Louisiana State University Health Sciences Center, 1900 Perdido Street New Orleans, LA 70112, USA.ORCID 0000-0002-5601-0430
Srinivas SriramulaDepartment of Pharmacology & Experimental Therapeutics, Louisiana State University Health Sciences Center, 1900 Perdido Street New Orleans, LA 70112, USA.ORCID 0000-0001-9937-1589
Jiaxi XuDepartment of Pharmacology & Experimental Therapeutics, Louisiana State University Health Sciences Center, 1900 Perdido Street New Orleans, LA 70112, USA.
Luke RestivoCardiovascular Center of Excellence, Louisiana State University Health Sciences Center, 533 Bolivar Street, New Orleans, LA 70112, USA.
Michelle A Mendiola PláDivision of Surgical Sciences, Department of Surgery, Duke University, Durham, NC 27710, USA.ORCID 0000-0001-9348-7708
Dawn E BowlesDivision of Surgical Sciences, Department of Surgery, Duke University, Durham, NC 27710, USA.ORCID 0000-0002-2781-1300
Andreas M BeyerDepartment of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0001-9129-7492
Xinping YueCardiovascular Center of Excellence, Louisiana State University Health Sciences Center, 533 Bolivar Street, New Orleans, LA 70112, USA.ORCID 0000-0002-4834-6612
Eric LazartiguesSoutheast Louisiana Veterans Health Care System, 2400 Canal Street, New Orleans, LA 70119, USA.ORCID 0000-0001-7290-0786
Catalin M FilipeanuDepartment of Pharmacology, School of Medicine, Howard University, 520 W St, NW, Washington, DC 20059, USA.ORCID 0000-0002-7298-9327
Louisiana State University Health Sciences Center New Orleans · USSoutheast Louisiana Veterans Health Care System · USDuke University · USHoward University · USEast Carolina University · USMedical College of Wisconsin · USSuez Canal University · EGUniversity of Maryland, Baltimore · US

Funding

Vascular and Cardiac Function Core - "Mentoring in Cardiovascular BiologyP30GM106392 · NIGMS · LSU HEALTH SCIENCES CENTER · PI NICHOLS, CHARLES D · 2014 to 2018
$5.5M
Targeting ACE2 ubiquitination for hypertensionR01HL150592 · NHLBI · LSU HEALTH SCIENCES CENTER · PI LAZARTIGUES, ERIC D · 2020 to 2023
$2.4M
Targeting ADAM17 maturation in resistant hypertension.R01HL163588 · NHLBI · LSU HEALTH SCIENCES CENTER · PI LAZARTIGUES, ERIC D · 2022 to 2025
$2.2M
New strategies to restore ACE2 compensatory activity in neurogenic hypertensionI01BX004294 · VA · SOUTHEAST LOUISIANA VETERANS HEALTH CARE · PI LAZARTIGUES, ERIC D · 2018 to 2021
–
BLRD VA I01 BX004294NHLBI NIH HHS R01 HL150592NHLBI NIH HHS R01 HL163588NIGMS NIH HHS P30 GM106392
6 · The paper itself

Abstract

aimsAngiotensin-converting enzyme 2 (ACE2) is a critical component of the compensatory renin-angiotensin system that is down-regulated during the development of hypertension, possibly via ubiquitination. However, little is known about the mechanisms involved in ACE2 ubiquitination in neurogenic hypertension. This study aimed at identifying ACE2 ubiquitination partners, establishing causal relationships and clinical relevance, and testing a gene therapy strategy to mitigate ACE2 ubiquitination in neurogenic hypertension. METHODS AND

resultsBioinformatics and proteomics were combined to identify E3 ubiquitin ligases associated with ACE2 ubiquitination in chronically hypertensive mice. In vitro gain/loss of function experiments assessed ACE2 expression and activity to validate the interaction between ACE2 and the identified E3 ligase. Mutation experiments were further used to generate a ubiquitination-resistant ACE2 mutant (ACE2-5R). Optogenetics, blood pressure telemetry, pharmacological blockade of GABAA receptors in mice expressing ACE2-5R in the bed nucleus of the stria terminalis (BNST), and capillary western analysis were used to assess the role of ACE2 ubiquitination in neurogenic hypertension. Ubiquitination was first validated as leading to ACE2 down-regulation, and Neural precursor cell-expressed developmentally down-regulated protein 4-2 (Nedd4-2) was identified as a E3 ligase up-regulated in hypertension and promoting ACE2 ubiquitination. Mutation of lysine residues in the C-terminal of ACE2 was associated with increased activity and resistance to angiotensin (Ang)-II-mediated degradation. Mice transfected with ACE2-5R in the BNST exhibited enhanced GABAergic input to the paraventricular nucleus (PVN) and a reduction in hypertension. ACE2-5R expression was associated with reduced Nedd4-2 levels in the BNST.

conclusionOur data identify Nedd4-2 as the first E3 ubiquitin ligase involved in ACE2 ubiquitination in Ang-II-mediated hypertension. We demonstrate the pivotal role of ACE2 on GABAergic neurons in the maintenance of an inhibitory tone to the PVN and the regulation of pre-sympathetic activity. These findings provide a new working model where Nedd4-2 could contribute to ACE2 ubiquitination, leading to the development of neurogenic hypertension and highlighting potential novel therapeutic strategies.

Indexed as

Angiotensin-Converting Enzyme 2HypertensionAngiotensin IIAnimalsMiceNedd4 Ubiquitin Protein LigasesPeptidyl-Dipeptidase AUbiquitinationUbiquitin-Protein LigasesUp-RegulationAce2 protein, mouseAngiotensin-Converting Enzyme 2Angiotensin IINedd4l protein, mouseNedd4 Ubiquitin Protein LigasesPeptidyl-Dipeptidase AUbiquitin-Protein LigasesAutonomic regulationBlood pressureGABASex differencesSympathetic drive

Identifiers

PMID37161607
PMCPMC10478751
OpenAlexW4376121536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.